Background. The Netherlands has provided unrestricted access to direct-acting antivirals (DAAs) since November 2015. We analyzed the nationwide hepatitis C virus (HCV) treatment uptake among patients coinfected with human immunodeficiency virus (HIV) and HCV.
On 1 November 2015, the Dutch government, among other countries in the world, expanded the reimbursement criteria and made DAA treatment possible for all patients with chronic HCV infection, regardless of their fibrosis stage. Scaling up HCV treatment is one of the interventions that, combined with increased harm reduction strategies and scaling up of testing, may lead to a lower incidence and prevalence of HCV infection and eventually to its elimination [2, 3] .
Here we describe the national HCV treatment uptake in HIV/ HCV-coinfected patients in the Netherlands, using data from the AIDS Therapy Evaluation in the Netherlands (ATHENA) HIV observational cohort. This cohort captures data on >98% of patients with HIV and in care in the Netherlands and is therefore highly representative of the overall Dutch HIV/HCV epidemic.
Monitoring Foundation (Stichting HIV Monitoring) is responsible for prospectively collecting demographic data and relevant HIV and treatment data, as well as data on comorbid conditions, including viral hepatitis coinfection, from HIV-infected persons living in the Netherlands and receiving care in one of these treatment centers. In addition, residual plasma from HIV viral load assays is stored in each center. This data collection is known as the ATHENA cohort [4] . The ATHENA cohort was initiated in 1998 and captures data from >98% of all patients with diagnosed HIV infection who are in care in the Netherlands. Data collection is still ongoing, and the database of the ATHENA cohort is locked and updated twice a year. This article includes the data from the February 2017 database lock, 15 months after unrestricted access to DAAs in the Netherlands. Furthermore, on 15 April 2017, each center was queried about HCV-infected patients whose treatment status was uncertain and/or whose sustained virological response (SVR) status had been pending in February 2017, in order to render data as up to date as possible.
Ethics Statement
At its inception, the ATHENA cohort was approved by the institutional review boards of all participating centers. Individuals can opt out after being informed by their treating physician of the purpose of data and sample collection. Data are pseudonymized and made available to investigators in a coded form. Coded data may be used for scientific purposes without further consent. For the purpose of our analysis, only existing data have been used and therefore no additional review or consent has been necessary.
Included Patients
A patient was considered linked to care if he or she had visited one of the 26 HIV clinics at least once and had not opted out of inclusion in the ATHENA cohort. Patients were included in the present analysis if they had ≥1 positive HCV RNA test result and if their HCV had not spontaneously cleared (HIV/HCVcoinfected patients defined as "linked to care"). Spontaneous clearance was defined as a negative HCV RNA test results after a positive result without initiation of HCV treatment. To label the HIV/HCV-coinfected patients who were "retained in care" on 1 February 2017, patients were excluded if they had died, had moved abroad or were lost to follow-up. Lost to follow-up was defined as the absence of a clinical visit after 1 January 2016.
Variables of Interest
Included patients were assessed for age, sex, country of origin, HIV transmission route, last known CD4 cell count and HIV-1 RNA measurement, the usage of combination antiretroviral therapy (cART), the presence of severe liver fibrosis, the usage of any HCV treatment, and the outcome of their last HCV treatment. HIV transmission route was used as a proxy for HCV transmission route. Severe liver fibrosis was defined as liver fibrosis stage F3 or higher (METAVIR scoring system), based on most recent available liver biopsy or transient elastography result (≥9.5 kPa). SVR was defined as a negative HCV RNA test result ≥24 weeks after the end of HCV treatment with a pegylated interferon-alfa-based regimen or as a negative HCV RNA test result ≥12 weeks after the end of HCV treatment with DAAs (SVR12).
HCV Treatment Cascade
Treatment uptake and outcome were assessed using a treatment cascade. In this cascade, every patient was depicted only once based on his or her most recent treatment. For example, if a patient was first treated unsuccessfully with a pegylated interferon-alfa-based regimen and subsequently with DAAs resulting in SVR12, only the last treatment was accounted for in this cascade. First, the proportion of patients who had received treatment was calculated. Second, the proportion of patients who had completed any treatment was calculated. Last, the proportion of patients who reached SVR was calculated. For every step in the cascade, the "gap" was also described (respectively the untreated patients, patients with ongoing treatment or awaiting SVR12 results and unsuccessfully treated patients).
Statistical Analysis
We used χ 2 tests to compare categorical variables. Differences were considered statistically significant at P ≤ .05.
RESULTS

HIV/HCV-Coinfected Patients
Of 23 574 HIV patients ever registered as having been linked to care on 1 February 2017, 2503 had ≥1 positive HCV RNA test result. After exclusion of patients whose HCV had spontaneously cleared (n = 514), 1989 HIV/HCV-coinfected patients who had ever been linked to care remained. Of these 1989 patients, 321 had died (of whom 42 had a confirmed liver-related death), 83 had moved abroad, and 114 were lost to follow-up (median duration of being lost to care, 5 years; interquartile range, 2-11 years), resulting in 1471 coinfected patients who were still retained in care in February 2017 ( Figure 1 ) and were included in the current analysis. Of these HIV/HCV-coinfected patients retained in care, 90% were male (1325 of 1471) and 67% were born in the Netherlands (983 of 1471; Table 1 ). The most commonly reported HIV transmission route was men who have sex with men (MSM) (69%; 1022 of 1471), followed by a history of injecting drug use (15%; 224 of 1471). For the remaining 15% (225 of 1471), HIV transmission had occurred through another route or had an unknown route. HCV genotype 1 was the most prevalent (61%; 896 of 1471), followed by HCV genotypes 4 and 3 (18% and 9%, respectively). Seventeen percent of patients (244 of 1471) had liver fibrosis of stage F3 or higher.
Treatment Uptake and Outcome
Of the included 1471 HIV/HCV-coinfected patients, 1284 had ever initiated HCV treatment between 2000 and 2017 ( Figure 2 ). Of these, 582 had been treated with an old HCV regimen (interferon-alfa, or pegylated interferon-alfa with or without ribavirin and with or without boceprevir or telaprevir), and 702 had received or were still receiving a currently used DAA regimen ( Figure 3 ). Of those treated with DAAs, 259 (37%) were previously treated with pegylated interferon-alfa-based antiviral regimens. A total of 187 patients had never started any form of HCV treatment, and 68 were in need of retreatment because prior HCV treatment had failed. Of these 68 patients, DAAs had failed in 14 and a (pegylated) interferon-alfa-based regimen had failed in 54.
Based on their last received treatment, 1124 of the 1192 patients (94%) who were known to have completed their HCV treatment reached SVR ( Figure 2 ). When analysis was restricted to patients known to have completed DAA treatment, 98% reached SVR12 (598 of 612). At the time of analysis, 76% (1124 of 1471) of the HIV/HCV-coinfected patients retained in care had reached SVR, and DAA treatment was still ongoing or treatment results were pending in 6% (92 of 1471). Overall, only 255 patients remain to be treated.
Of the 1284 patients who ever started treatment, 743 started their last treatment in 2014, 2015 or 2016. Shortly after unrestricted access to DAAs, 176, 226 and 86 patients started treatment in the fourth quarter of 2015 and the first and second quarters of 2016, respectively; in all other quarters, the number of patients who started treatment was <50 (Figure 4 ).
cART During Last HCV Treatment
The cART regimens at the time of HCV treatment initiation are listed in Table 1 . Of the 702 patients who were treated with a currently used DAA regimen, 191 (27%) had switched cART regimen in the 3 months before HCV treatment initiation. For 130 of those patients, "start of HCV treatment" was recorded in the database as reason for the cART switch; for the other 61, the reason was not explicitly recorded. Of 582 patients who were treated with an old HCV treatment regimen, 109 (19%) had switched cART regimen in the 3 months before HCV treatment initiation. For 54 of those patients, "start of HCV treatment" was recorded in the database as reason for the cART switch.
Stratification by Liver Fibrosis Stage F3-F4
Of the 244 patients classified with liver fibrosis stage F3 or higher and retained in care on 1 February 2017, 79% (192 of 244) had achieved SVR and 5% (13 of 244) were still undergoing DAA treatment. Thirty-nine patients with severe liver disease remain to be treated (previous treatment failed in 14 patients, and 25 were never treated).
Stratification by HIV Transmission Route
Findings in MSM
A total of 1022 HIV/HCV-coinfected patients identified as being MSM were retained in care as of 1 February 2017. SVR was achieved in 83% (844 of 1022), significantly higher than the 76% with SVR in the overall population (P < .001). In 6% (66 of 1022), DAA treatment was still ongoing or treatment results were pending. Thus, only 112 MSM remain to be treated.
Findings in Persons Who Injected Drugs
Of the 224 HIV/HCV-coinfected patients retained in care as of 1 February 2017 and classified as persons who (formerly) injected drugs (PWID), 57% (127 of 224) reached SVR, which was significantly lower than in the overall population (P < .001). In 8% (18 of 224), DAA treatment was still ongoing or treatment results were pending.
Characteristics of Patients Who Never Started Treatment
In the patients who never started treatment (n = 187), the proportion of women was significantly higher than the proportion among patients who ever received treatment (n = 1284) (20% vs 8%; P < .001). The proportion of MSM was lower (39% vs 74%; P < .001) and the proportion of PWID was higher (35% vs 12%; P < .001). Four percent of patients untreated for HCV never received cART, compared with 1% in the group treated for HCV (P < .001). Region of origin differed significantly between the 2 groups (overall P < .001), with a higher proportion of patients from the Netherlands among the treated patients (69% vs 55%) and a lower proportion from the Caribbean and Latin America (6% vs 11%). Furthermore, HCV genotype differed significantly between the 2 groups (overall P < .001), with a higher proportion of genotype 1 (62% vs 51%) and a lower proportion of genotype 3 (8% vs 14%) among the treated than among the untreated patients (51% and 14%). The presence of severe liver fibrosis (METAVIR score F3 or higher) did not differ significantly between these 2 groups.
Characteristics of Patients With Failed Treatment
Overall, treatment failed in 68 patients, DAAs in 14 and a pegylated interferon-alfa-based regimen in 54. Compared with the patients who achieved SVR (n = 1124), the proportion of PWID was higher in the patients with failed treatment (21% vs 11%; P = .02), and the proportion of MSM was lower (59% vs 75%; P = .003). Furthermore, 3% of the patients with failed HCV treatment never received cART, compared with 1% in the group who achieved SVR (P = .02). Other variables did not differ significantly between the 2 groups.
Of the patients in whom DAAs failed (n = 14), 9 were MSM, 2 were PWID, and 3 had another HIV transmission route. Seven patients were infected with genotype 1a, 5 with genotype 4, and 2 with another HCV genotype. Three patients had severe liver fibrosis (METAVIR score F3 or higher). 
DISCUSSION
As of 1 February 2017 and only 15 months after DAAs were made available to all patients with chronic HCV in the Netherlands, 76% of the Dutch HIV/HCV-coinfected patients in care had been successfully treated for HCV. Another 6% are still undergoing DAA treatment or have completed treatment but are awaiting SVR12. The majority of this 6% can be expected to also have their HCV infection cured, because realworld SVR rates after DAA treatment in HIV/HCV-coinfected patients are well above 90% [5] [6] [7] [8] . Our results demonstrate that in resource-unconstrained settings, a very high treatment uptake is possible in HIV/HCV-coinfected patients within only 15 months after unrestricted availability of DAAs. Treatment uptake and HCV cure rates were highest in MSM and significantly higher than in other categories of coinfected patients. Only 112 HIV/HCV-coinfected MSM remain to be treated. In the Netherlands, in contrast to other countries, ongoing HCV transmission occurs mainly among HIV-infected MSM [9] ; transmission among PWID is nearly nonexistent as a result of successful harm reduction policies [10] . Therefore, it is promising that treatment uptake is highest among MSM, which may help reduce ongoing HCV transmission in the Netherlands. However, the fact that treatment uptake in HIV/ HCV-coinfected PWID in care was significantly lower than in the overall population of HIV/HCV-coinfected patients is an important signal that might reflect social, medical, psychiatric and/or substance use-associated factors or barriers perceived by practitioners, as reviewed extensively by Grebely et al [11] .
Our study has several strengths. The data we analyzed were derived from the longstanding ATHENA cohort of HIV-infected patients and include data on HCV status and treatment. This cohort is representative of all HIV-infected patients in the Netherlands, because it captures data from >98% of all HIVinfected patients in care. In addition, for this study an extra query was performed by contacting each HIV treatment center with a list of HCV-coinfected patients whose treatment status remained uncertain or whose SVR12 results were pending in February 2017. As a result of this query we have made the data of this study as up to date as possible. To our best knowledge, this is the first study that provides truly nationwide data on HCV treatment uptake and cure rates after unrestricted DAA availability for chronic hepatitis C in HIV/HCV-coinfected patients. If this rapid treatment scale up is continued, it may contribute to the future elimination of HCV among HIV/HCV-coinfected patients in the Netherlands. Of note however, additional harm reduction strategies and scaling up of HCV testing will probably be necessary to eventually reach elimination [2, 3] .
Our study also has some limitations. First, only the patients who were retained in care could be analyzed and therefore we were unable to provide data on the 114 patients who were lost to follow-up. However, these 114 patients represent only 6% (114 of 1989) of the HIV/HCV-coinfected patients overall. Collaboration between different stakeholders could possibly lead to (re)identification of these patients and further elimination of HCV from the HIV/HCV-coinfected population. Second, a certain proportion of HCV infections in this population will remain undiagnosed, because alanine aminotransferase levels may occasionally remain within normal limits after HCV infection [12] . However, 99% of HIV-infected patients currently in care in the Netherlands have been tested for HCV at least once [4] . A third limitation is that only the most recent treatment and its outcome was included in the cascade. This is an appropriate method to visualize the overall treatment uptake, but in the calculation of the SVR rate it may have led to an overestimation, because for patients in whom the first DAA treatment failed and the second was successful, the calculation took only the second result into account. Real-world SVR rates found in other studies in HIV/HCV-coinfected patients are indeed lower than the 98% that we report [5] [6] [7] [8] . Furthermore, owing to the cross-sectional design of our analysis, HCV reinfections after DAA treatment could not be taken into account. Because HCV reinfections are common in HIV-infected MSM [13, 14] , a certain proportion of the population will become reinfected with HCV and therefore again be in need of effective treatment.
Although treatment uptake and HCV cure rates are high, the group of patients that remains to be treated will be the most challenging. To target this remaining subgroup of HIV/HCVcoinfected patients, we provided each HIV treatment center with a coded list of patients who, according to the information available in the ATHENA database, remain in need of curative treatment, in order to facilitate their identification and reevaluation.
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